 A total of 47 heavily pre-treated patients median of six prior therapies with immune thrombocytopenia ITP have been enrolled with a median follow-up of 18 weeks. Data from this trial are being presented by David Kuter, M.D., director of Clinical Hematology at Massachusetts General Hospital and professor of Medicine at Harvard Medical School, at a virtual session of the European Hematology Association EHA. 